RxDoctor Payments Data

Laura Divoky, MD

Cardiovascular Disease · Braselton, GANPI 1336439991

Payments from drug & device makers

$5,023in general payments, 2019–2025

Across 286 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Pfizer$662
  • Merck$520
  • Novartis$479
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$461
  • Johnson & Johnson$452
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$5,006100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,023 in reported general payments places this provider in the 65th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$308,767
Medicare patients
2,157
Services billed
8,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban508$536,078
Repatha SureclickEvolocumab216$204,128
XareltoRivaroxaban147$174,625
EntrestoSacubitril/Valsartan121$156,506
Praluent PenAlirocumab67$48,924
JardianceEmpagliflozin36$43,075
FarxigaDapagliflozin Propanediol28$38,326
MultaqDronedarone Hcl11$20,746
BrilintaTicagrelor21$19,770
NexlizetBempedoic Acid/Ezetimibe22$14,147
NexletolBempedoic Acid17$12,245
Metoprolol Succinate432$5,903
Rosuvastatin Calcium433$5,151
Atorvastatin Calcium530$4,194
Ranolazine ErRanolazine37$3,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$662$536,078508 claims
Johnson & JohnsonXarelto$452$174,625147 claims
NovartisEntresto$479$156,506121 claims
AstraZenecaFarxiga, Brilinta$111$58,09649 claims
Boehringer IngelheimJardiance$118$43,07536 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$24$26,39239 claims
Sanofi-aventis U.S. LLCMultaq$74$20,74611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Braselton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →